Immunotherapy

The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.

The move will add Chronix's proprietary technology for blood-based immune therapy monitoring and transplant rejection testing to Oncocyte's existing test menu.

The company's two largest investors will purchase $25 million of its common shares, with proceeds supporting ongoing test commercialization.

Investigators are conducting a prospectively designed, retrospective study of archived material from the NeoTRIPaPDL1 triple negative breast cancer trial.

Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.

The draft LCD would cover the Signatera minimal residual disease test for several solid tumor types and indications, including immunotherapy response monitoring.

HalioDx's Immunoscore test, which measures host immune response at the tumor site, will be used to select patients for the trial.

Revenue growth in Q2 was driven by strong sales of the company's Panorama noninvasive prenatal test and Horizon carrier screening test.